Theralia AB

Theralia AB is one of the 10 finalists of Startup World Cup Sweden Regional and will be competing to represent Sweden at the Global Grand Finale in San Francisco💥 🚀

We are thrilled to be part of INCATE 🎊 This collaboration will significantly acceletate the development of our novel targeted antimicrobials, TOUCANs, to save patients suffering from multidrug-resistant bacterial infections 🤝

Our co-founders Frank J. Hernandez and Baris Ata Borsa presented the latest developments on the TOUCAN Technology in Uppsala Antibiotic Days. Many thanks to Uppsala Antibiotic Center and all the organizers for this great event!

We are excited to be attending @#ECCMID2024 in Barcelona and present Theralia AB`s TOUCAN Technology in the Therapeutic Pipeline Corner on 28th April 🚀 💫 Don`t miss this special event if you are one of the 10.000+ participants of this great congress!!!

Baris Ata Borsa forskar på antimikrobiell resistens och har utvecklat en teknik som producerar antibiotika som riktas mot patogener i kroppen som orsakar infektion. – Med den här tekniken kan vi erbjuda en säkrare behandling med mindre biverkningar för patienter med cancer eller svåra infektioner, säger han. Nyligen fick Baris Ata Borsas forskningsprojekt 50 000 kronor från VFN-programmet, som ett av fyra projekt som East Sweden Medtech finansierar. VFN står för Verifiering för nyttiggörande och är ett program vid Linköpings universitet för aktiviteter som ska bidra till att forskningsresultat skapar nytta. Läs mer här: https://lnkd.in/dpDA8_39 Region Östergötland Linköping University

Newly released 'The Founder Talk' 👉 https://lnkd.in/gyyZtrkh The Founder Talk | Featuring Frank J. Hernandez, Chief Scientific Officer at Theralia AB | Episode 211 Theralia AB is a pioneering biotech company dedicated to revolutionizing how nucleoside analogs are employed in diverse therapeutic landscapes. #startup #startupfunding #entrepreneur #earlystage #fundraising #equitymatch #FinancialServices #medtech

We are delighted to be selected as one of the 10 companies for the Start-up Pitch Event at AMR Conference in Basel on 6-7th of March 🚀 We will present our novel platform, TOUCAN Technology, to fight AMR 🌟

#WorldCancerDay #AntibioticResistance Dr. Honar Cherif: "My patients can receive 5-10 courses of antibiotics during their cancer treatment." He continues: "A worrying development has been reported in many European countries for some years now. Infections caused by multi-resistant bacteria such as MRSA and ESBL do not respond to the broad-spectrum antibiotics we use to manage infections in these immunocompromised patients. If we get to a point where we can not prevent and treat these serious infections, we will have a very difficult time treating cancer with chemotherapy. This, of course, has catastrophic consequences." Union for International Cancer Control (UICC) Cancerfonden Kreftforeningen Read full interview 👇 https://lnkd.in/ek-rMQq

We are proud of being an innovative biotech company of the European Rising Innovation City of the year 💫